The United States Food and Drugs Administration has filed a complaint against Ranbaxy Laboratories Ltd with a local court, saying that the quality of drugs made at one of its domestic plants is poor, according to a person familiar with the matter.

Ranbaxy has defended itself saying the court has not initiated any proceedings against the company and the company strongly denies these allegations contained in the motion. A motion has been filed, but not granted, with FDA seeking certain documents from Ranbaxy. No legal proceedings have been initiated against Ranbaxy. The company will continue to cooperate with the US Department of Justice and we continue to remain committed to providing high-quality generics to the US markets and patients.

US prosecutors are probing allegations that Ranbaxy faked test data to make it appear that its products met federal quality standards, the Star-Ledger of Newark, New Jersey reported, citing court papers.

Ranbaxy drugs had too little or too much active ingredient or lacked the labelled shelf life and didn't meet US FDA standards, federal prosecutors said in court papers filed July 3 in US District Court of Maryland, according to the Star-Ledger.